The development of massively parallel sequencing technology has allowed the identification of an increasing number of recurrent somatic mutations in myelodysplasitc syndromes (MDS). 1 Although identification of these mutations has improved our understanding of the pathogenesis of MDS, a snapshot of molecular alterations at single time point (often at time of diagnosis) does not fully represent the dynamic nature of MDS. Recent whole-genome sequencing of sequential bone marrow samples in small numbers of MDS patients has indicated that mutations could follow a dynamic pattern. 2 Therefore, it is becoming apparent that genetic abnormalities of MDS should be analyzed in a time-dependent manner.
FLT3 molecular alterations (FLT3m), including internal tandem duplication (ITD) and tyrosine kinase domain mutation (TKD), and RAS mutations (RASm) are both classified as class 1 mutations in leukemia. 3 FLT3m or RASm are identified in approximately 15-30% of acute myeloid leukemia (AML) patients in mutually exclusive manner. 4 In contrast to AML, FLT3m and RASm are less frequent in MDS with reported incidence of 0.6-6% and 3-6%, respectively. 1, 5 The presence of these mutations has not been associated with difference in prognosis. 1, 6, 7 Previous studies, however, focused on the incidence and prognostic impact of FLT3m or RASm at initial diagnosis and only a few studies have evaluated dynamic or temporal acquisition of FLT3m or RASm in MDS. [8] [9] [10] In this context, we sought to study the incidence of dynamic acquisition of FLT3m and RASm in lower risk MDS (LR-MDS) and its impact on transformation and survival.
We retrospectively studied 278 patients with International Prognostic Scoring System 11 low-or intermediate-1 (Int-1)-risk  MDS (defined as LR-MDS) 1 who were referred to our institution between 2000 and 2010 and had both FLT3m and RASm analysis at least twice (at time of referral and at least once thereafter). Molecular alterations in FLT3 (both ITD and TKD ¼ codons 835 and 836) were detected by semiquantitative polymerase chain reactioncapillary electrophoresis. Point mutations in codons 12, 13 and 61 of KRAS and NRAS were detected by PCR followed by pyrosequencing. The sensitivity of these assays for mutation detection was 2.5% and 5%, respectively. Prognostic correlation between acquisition of FLT3m or RASm and transformation-free and overall survival (TFS and OS) was evaluated by Cox proportional hazards regression where acquisition of FLT3m or RASm was fitted as a time-dependent covariate. The study protocol was approved by the Institutional Review Board at MD Anderson Cancer Center.
Baseline clinical characteristics between patients with FLT3m or RASm acquisition and patients without acquisition are summarized in Table 1 Table 6 ).
Class I mutations are rare in MDS, whereas mutations in RNA splicing or epigenetic regulating genes are more frequently identified. 1 Of importance, very few of those mutations have independent prognostic impact in LR-MDS, implying that additional molecular hits may be required for disease progression and transformation. 1 We hypothesized that class I mutations such as FLT3m and RASm could be dynamically acquired in LR-MDS resulting in proliferative advantage and transformation from MDS to secondary AML (sAML). Although incidence of FLT3m or RASm was low (7%) in the 280 LR-MDS patients analyzed, acquisition was observed in 23% (17 out of 74) of the patients who transformed to sAML. Multivariate analysis indicated very strong association between FLT3m or RASm acquisition and worse TFS and OS. Our findings suggest that activation of FLT3 or RAS pathway can be a 'transforming' event or driver of transformation in a subset of patients with LR-MDS.
Several studies have also reported smaller series of FLT3m or RASm acquisition in MDS and sAML. [8] [9] [10] 12, 13 An unique finding of this study, is the identification of four patients with FLT3m or RASm acquisition before transformation. Serial molecular testing between diagnosis and transformation enabled early detection in these patients. On the other hand, molecular testing was not repeated until time of transformation in 13 patients whose detection was at the time of transformation. If indeed FLT3m or RASm acquisition is the driving event of transformation, it would be clinically informative to detect mutational acquisition before transformation. Therefore, during the clinical follow-up of patients with LR-MDS, mutation analysis of FLT3m or RASm could be considered when patients show clinical deterioration such as increasing transfusion dependency or manifestation of proliferative disease.
Response to the treatment once patients progressed to sAML after acquiring FLT3m or RASm was poor (Supplementary Table 1 ). Thus, clones that acquired FLT3m or RASm should be detected earlier and eliminated before they progress to sAML. Various clinical approaches could be considered using molecularly targeted agents such as FLT3 or MEK inhibitors. For instance, we observed durable complete remission in patients of high-risk MDS with FLT3-ITD who were treated with 5-azacitidine and sorafenib.
14 Depending on the donor availability, bridging to stem cell transplant might also be justified when acquisition of FLT3m or RASm occur, given high risk of transformation and poor prognosis of these patients.
We acknowledge several limitations in our study. First one is the sensitivity of the method for detecting FLT3m or RASm. Patients who 'acquired' FLT3m or RASm in our analysis may have had undetectable subclones harboring FLT3m or RASm at original diagnosis, thus representing clonal expansion instead of acquisition. More sensitive approaches such as next-generation sequencing should be performed to confirm our findings in the future. Second, not all the patients with MDS in our institution underwent FLT3m or RASm analysis more than twice and this created selection bias. Patients who were analyzed in this study could have been tested for mutations because of suspicion for increased risk of disease progression or transformation. Therefore, actual incidence of FLT3m and RASm acquisition could be lower in Table 1 . Baseline characteristics of studied patients (N ¼ 278) 
Letters to the Editor overall LR-MDS population. Finally, because of the retrospective nature of the study, timing and frequency of FLT3m or RASm testing was not controlled in all patients and some patients had more frequent test while others had only been tested twice. In order to understand the exact incidence and timing of FLT3m or RASm acquisition, mutation analysis should be performed in prospectively controlled manner. Nonetheless, with all the above limitations, the strong association between FLT3m and RASm acquisition and leukemic transformation in the current cohort still suggests the important role of these molecular alterations in the disease progression of LR-MDS.
In conclusion, approximately 7% of patients with LR-MDS in our cohort acquired FLT3m and/or RASm during their clinical course, and acquisition of such alterations/mutations were strongly associated with AML transformation, suggesting their role in driving transformation. Acquisition of FLT3m or RASm may be predictive of transformation and future studies using more sensitive methods to detect mutations are warranted to confirm our findings.
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